Aktis Oncology starts Phase 1b trial of AKY-2519 for advanced prostate cancer targeting B7-H3 tumors

Aktis Oncology has initiated a Phase 1b clinical trial for AKY-2519, a targeted radioconjugate aimed at treating metastatic castration-resistant prostate cancer (mCRPC) expressing B7-H3. This trial includes patients both new to and experienced with PLUVICTO® therapy, with preliminary results expected in 2027. The company also plans a second Phase 1b basket trial for other B7-H3 expressing solid tumors like lung and colorectal cancers later in 2026, aiming to broaden treatment options and gather robust clinical data. This development addresses unmet needs in prostate cancer treatment, especially for patients ineligible or unresponsive to current PSMA-targeted therapies.